FLEX ADJUVANT PUBLICATIONS & ABSTRACTS

Clinical evidence from FLEX


Evidence / Adjuvant / FLEX

AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer

Publication: ESMO 2026 Authors: L. Van't Veer; Laboratory Medicine, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, United States of America Title: AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer Abstract Background: MammaPrint (MP) is Read More

70-Gene Signature Provides Prognostic Value Beyond Ki67 in HR+HER2– Early Breast Cancer (EBC)

Publication: ESMO 2026 Authors: Michael Gnant, Mehran Habibi, Adam Brufsky, Laila Samiian, Sasha Davis, Eduardo Dias, Virginia Borges, Kent Hoskins, VK Gadi, Cynthia Osborne, Rakhshanda Layeequr-Rahman, Alfredo Santillan, Harshini Ramaswamy, Raquel Weber, Andrea Menicucci, William Audeh and Joyce O’Shaughnessy. Title: 70-Gene Signature Provides Prognostic Value Beyond Ki67 in HR+HER2– Read More

Impact of Germline BRCA1 and BRCA2 Mutations on 70-Gene Signature Risk for patients enrolled in the FLEX Study

Publication: ESMO 2026 Authors: Amir Sonnenblick (first and presenting), Mehran Habibi, Laura Lee, Eduardo Dias, Alfredo Santillan, Beth Sieling, Nicole Sookhan, Laila Samiian, Sasha Strain, Jaime Alberty, Massimo Cristofanelli, Priscilla McAuliffe, Samuel Benjamin, Sahra Uygun, Nicole Stivers, Raquel Weber, Andrea Menicucci, Willan Audeh, Joyce O'Shaughnessy Title: Impact of Germline Read More

Prediction of Anthracycline Benefit in Hormone Receptor– Positive, Human Epidermal Growth Factor Receptor 2– Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study

Publication: JCO Precis Oncol, June 2026 DOI https://doi.org/10.1200/PO-25-01285 Authors: Joyce O'Shaughnessy et al. Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstract Purpose: Randomized trials have not demonstrated clear benefit from anthracyclines for patients with hormone receptor–positive, human epidermal growth Read More

Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers

Publication: ASCO 2026, Abstract #561 Authors: Steve Isakoff Title: Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers Abstract Background: Homologous recombination deficiency (HRD) is a biomarker for impaired DNA repair proficiency and genomic instability, associated with sensitivity to DNA-damaging agents. Read More

HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study

Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et al. Title: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study Introduction: Women ≥ 70 years of age are less likely to receive chemotherapy (CT) due to Read More